# An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

> **NCT01924793** · PHASE2 · COMPLETED · sponsor: **Ansun Biopharma, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Parainfluenza

## Interventions

- **DRUG:** DAS181-F02 Dry Powder in Bulk
- **DRUG:** DAS181-F02 Nebulized Formulation Inhaled Dose

## Key facts

- **NCT ID:** NCT01924793
- **Lead sponsor:** Ansun Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01924793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01924793, "An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01924793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*